This article first appeared on GuruFocus .
Release Date: June 02, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
PetMed Express Inc ( NASDAQ:PETS ) made significant financial, operational, and cultural improvements in fiscal year 2026, aiming for sustainable long-term results.
-
The company regained critical regulatory compliance and improved internal controls, remediating three previously disclosed material weaknesses.
-
There was a sequential quarterly increase in fourth quarter net sales, marking the first Q4 sequential increase since fiscal year 2024.
-
Cost reduction efforts led to exiting underperforming vendor relationships, yielding approximately $6.1 million in annualized savings.
-
PetMed Express Inc ( NASDAQ:PETS ) completed several important technology and infrastructure initiatives, including a new ERP system and fraud prevention system, enhancing operational efficiency.
Negative Points
-
Net sales for the full fiscal year 2026 were down 21.1%, with a 15.6% decline in the fourth quarter compared to the prior year.
-
The company reported a net loss of $57.3 million for the full fiscal year, significantly higher than the $6.3 million loss in the prior year.
-
Several significant non-recurring accounting entries, including a $26.7 million non-cash goodwill impairment and a $2.1 million wholesale inventory write-down, impacted financial results.
-
PetMed Express Inc ( NASDAQ:PETS ) incurred $4.5 million in non-recurring legal, professional, and executive severance costs related to a whistleblower investigation.
-
Despite improvements, the company faced challenges with a decline in prescription medication sales, impacting overall revenue.
Q & A Highlights
Q: Can you provide more details on the financial improvements made in the second half of fiscal year 2026? A: Leslie Campbell, Interim CEO and President, explained that PetMed Express made significant progress in stabilizing its core business and strengthening its foundation for future value creation. This included regaining critical regulatory compliance, improving internal controls, and achieving a sequential quarterly increase in Q4 net sales, the first since fiscal year 2024.
Q: What were the main factors contributing to the decline in net sales for fiscal year 2026? A: Doug Krulich, Interim Principal Financial Officer and Chief Accounting Officer, stated that the 21.1% decline in net sales was primarily driven by a decrease in prescription medication sales. However, there was a modest sequential improvement in Q4, indicating positive momentum.
Q: How did the company address its cost structure and operational performance? A: Leslie Campbell highlighted that PetMed Express made meaningful progress on cost reduction efforts, including exiting underperforming vendor relationships, which will yield approximately $6.1 million in annualized savings. The company also reorganized to optimize headcount productivity in its pharmacy, call center, and distribution centers, improving both operational performance and customer experience.
Q: What strategic initiatives are planned for fiscal year 2027? A: Leslie Campbell mentioned that the company plans to focus on operational excellence, driving sustainable long-term results, and delivering value for shareholders. This includes improving customer retention, expanding market footprint through B2B relationships, and leveraging technology and infrastructure improvements.
Q: What was the outcome of the unsolicited acquisition offers received by the company? A: Leslie Campbell reported that the Board evaluated the proposals and determined it was in the best interest of the company and its stockholders not to proceed with either of the publicly announced proposals. PetMed Express will continue to operate as an independent publicly traded company but remains open to considering future proposals.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
